Connection
Co-Authors
This is a "connection" page, showing publications co-authored by Wesley Nuffer and Jennifer Trujillo.
|
|
Connection Strength |
|
|
|
|
|
4.348 |
|
|
|
-
Nuffer W, Williams B, Trujillo JM. A review of sotagliflozin for use in type 1 diabetes. Ther Adv Endocrinol Metab. 2019; 10:2042018819890527.
Score: 0.703
-
Nuffer W, Guesnier A, Trujillo JM. A review of the new GLP-1 receptor agonist/basal insulin fixed-ratio combination products. Ther Adv Endocrinol Metab. 2018 Mar; 9(3):69-79.
Score: 0.619
-
Trujillo JM, Nuffer WA. Impact of Sodium-Glucose Cotransporter 2 Inhibitors on Nonglycemic Outcomes in Patients with Type 2 Diabetes. Pharmacotherapy. 2017 Apr; 37(4):481-491.
Score: 0.581
-
Nuffer WA, Trujillo JM. Liraglutide: A New Option for the Treatment of Obesity. Pharmacotherapy. 2015 Oct; 35(10):926-34.
Score: 0.527
-
Trujillo JM, Nuffer W. GLP-1 receptor agonists for type 2 diabetes mellitus: recent developments and emerging agents. Pharmacotherapy. 2014 Nov; 34(11):1174-86.
Score: 0.495
-
Trujillo JM, Nuffer W. Albiglutide: a new GLP-1 receptor agonist for the treatment of type 2 diabetes. Ann Pharmacother. 2014 Nov; 48(11):1494-501.
Score: 0.488
-
Tall Bull S, Nuffer W, Trujillo JM. Tirzepatide: A novel, first-in-class, dual GIP/GLP-1 receptor agonist. J Diabetes Complications. 2022 12; 36(12):108332.
Score: 0.214
-
Trujillo JM, Nuffer W, Smith BA. GLP-1 receptor agonists: an updated review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2021; 12:2042018821997320.
Score: 0.192
-
Trujillo JM, Wettergreen SA, Nuffer WA, Ellis SL, McDermott MT. Cardiovascular Outcomes of New Medications for Type 2 Diabetes. Diabetes Technol Ther. 2016 12; 18(12):749-758.
Score: 0.142
-
Nuffer W, Trujillo JM, Megyeri J. A Comparison of New Pharmacological Agents for the Treatment of Obesity. Ann Pharmacother. 2016 May; 50(5):376-88.
Score: 0.135
-
Trujillo JM, Nuffer W, Ellis SL. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther Adv Endocrinol Metab. 2015 Feb; 6(1):19-28.
Score: 0.126
-
Nuffer W, Trujillo JM, Ellis SL. Technosphere insulin (Afrezza): a new, inhaled prandial insulin. Ann Pharmacother. 2015 Jan; 49(1):99-106.
Score: 0.123
|
Connection Strength
The connection strength for concepts is the sum of the scores for each matching publication.
Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.
|